Literature DB >> 12839925

Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium.

Andrea Flesken-Nikitin1, Kyung-Chul Choi, Jessica P Eng, Elena N Shmidt, Alexander Yu Nikitin.   

Abstract

Alterations in p53 and Rb pathways are observed frequently in epithelial ovarian cancer (EOC).However, their roles in EOC initiation remain uncertain. Using a single intrabursal administration of recombinant adenovirus expressing Cre, we demonstrate that concurrent inactivation of p53 and Rb1 is sufficient for reproducible induction of ovarian epithelial carcinogenesis in mice homozygous for conditional gene alleles. Similarly to progression of disease in women, ovarian neoplasms spread i.p., forming ascites, and metastasize to the contralateral ovary, the lung, and the liver. These results establish critical interactions between p53 and Rb1 pathways in EOC pathogenesis, and provide a genetically defined immunocompetent mouse model of sporadic EOC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12839925

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  119 in total

1.  MET-dependent cancer invasion may be preprogrammed by early alterations of p53-regulated feedforward loop and triggered by stromal cell-derived HGF.

Authors:  Chang-Il Hwang; Jinhyang Choi; Zongxiang Zhou; Andrea Flesken-Nikitin; Alexander Tarakhovsky; Alexander Yu Nikitin
Journal:  Cell Cycle       Date:  2011-11-15       Impact factor: 4.534

2.  Wild-type p53 controls cell motility and invasion by dual regulation of MET expression.

Authors:  Chang-Il Hwang; Andres Matoso; David C Corney; Andrea Flesken-Nikitin; Stefanie Körner; Wei Wang; Carla Boccaccio; Snorri S Thorgeirsson; Paolo M Comoglio; Heiko Hermeking; Alexander Yu Nikitin
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-09       Impact factor: 11.205

3.  Measuring the intra-individual variability of the plasma proteome in the chicken model of spontaneous ovarian adenocarcinoma.

Authors:  Adam M Hawkridge; Rebecca B Wysocky; James N Petitte; Kenneth E Anderson; Paul E Mozdziak; Oscar J Fletcher; Jonathan M Horowitz; David C Muddiman
Journal:  Anal Bioanal Chem       Date:  2010-07-17       Impact factor: 4.142

4.  E2f binding-deficient Rb1 protein suppresses prostate tumor progression in vivo.

Authors:  Huifang Sun; Yanqing Wang; Meenalakshmi Chinnam; Xiaojing Zhang; Simon W Hayward; Barbara A Foster; Alexander Y Nikitin; Marcia Wills; David W Goodrich
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

5.  Induced mitotic recombination of p53 in vivo.

Authors:  Wei Wang; Madhuri Warren; Allan Bradley
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-05       Impact factor: 11.205

Review 6.  Role of p53 and Rb in ovarian cancer.

Authors:  David C Corney; Andrea Flesken-Nikitin; Jinhyang Choi; Alexander Yu Nikitin
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

7.  Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer.

Authors:  Ludmila Szabova; Chaoying Yin; Sujata Bupp; Theresa M Guerin; Jerome J Schlomer; Deborah B Householder; Maureen L Baran; Ming Yi; Yurong Song; Wenping Sun; Jonathan E McDunn; Philip L Martin; Terry Van Dyke; Simone Difilippantonio
Journal:  Cancer Res       Date:  2012-05-22       Impact factor: 12.701

8.  Molecular imaging reveals a role for AKT in resistance to cisplatin for ovarian endometrioid adenocarcinoma.

Authors:  Hanxiao Wang; Stefanie Galbán; Rong Wu; Brittany M Bowman; Amanda Witte; Katrin Vetter; Craig J Galbán; Brian D Ross; Kathleen R Cho; Alnawaz Rehemtulla
Journal:  Clin Cancer Res       Date:  2012-10-24       Impact factor: 12.531

9.  Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment.

Authors:  Jingfang Zheng; Imelda Mercado-Uribe; Daniel G Rosen; Bin Chang; Peishu Liu; Gong Yang; Anais Malpica; Honami Naora; Nelly Auersperg; Gordon B Mills; Robert C Bast; Jinsong Liu
Journal:  Cell Cycle       Date:  2010-01-05       Impact factor: 4.534

Review 10.  Tailoring to RB: tumour suppressor status and therapeutic response.

Authors:  Erik S Knudsen; Karen E Knudsen
Journal:  Nat Rev Cancer       Date:  2008-09       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.